Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(2000): Chemnitz JM+, Med Klin (German) 95, 96
(2000): Tsai H-M+, AnnInternMed132, 794
(1999): Bennett CL+, AnnInternMed159, 2524
(1999): Chen DK+, Arch Intern Med 159, 311
(1999): Elangovan L, Arch Int Med 159, 1624
(1999): Mauro M+, Blood 94, 1–646a
(1999): Steinhubl SR+, JAMA 281, 806
(1998): Bennett CL+, AnnInternMed128, 541
(1998): Bennett CL+, Lancet 352, 1036
(1998): Jamar S+, Acta Cardiol 53, 285
(1998): Mukamal KJ+, AnnInternMed129, 837
(1998): Muszkat M+, Pharmacotherapy 18, 1352
(1997): Kupfer Y+, NEnglJMed337, 1245
(1996): Wysowski DK+, JAMA 276, 952
(1991): Page Y+, Lancet 337, 774
(1990): McTavish D+, Drugs 40, 238 (1–5%)
(1990): Takishita S+, NEnglJMed323, 1487
(1989): Hass WK+, NEnglJMed321, 501 (4%)
(1984): Stiegler H+, Dtsch Med Wochenschr (German) 109, 1240
(1–5%)
(1982): de Fraiture WH+, Ned Tijdschr Geneeskd (Dutch)
126, 1051
Rash (sic) (5.1%)
(2006): Makkar K+, Ann Pharmacother 40(6), 1204 (with
clopidogrel)
(2005): Grabowski M+, Pol Arch Med Wewn. 114(4), 974
(1999): Quinn MJ+, Circulation 100, 1667
(1999): Whetsel TR+, Pharmacotherapy 19, 228
Side effects (sic) (8%)
(1984): Stiegler H+, Dtsch Med Wochenschr (German) 109, 1240
(8%)
Stevens–Johnson syndrome (